Telisotuzumab adizutecan is under clinical development by AbbVie and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 74% phase transition ...

ABBV-291 is under development for the treatment of relapsed or refractory (R/R) non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and ...

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock ...

Medtronic has been raising its dividend for 47 consecutive years and it offers a high yield now. Bristol Myers Squibb offers ...

Shares of AbbVie Inc. ABBV inched 0.99% higher to $181.22 Friday, on what proved to be an all-around favorable trading ...

Researchers design a new way to more reliably evaluate AI models' ability to make clinical decisions in realistic scenarios that closely mimic real-life interactions. The analysis finds that ...

Corporate borrowing surged to a record in 2024, up over a third from a year earlier as companies like AbbVie and Cisco looked ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $179.44 which represents a slight increase of $1.74 or 0.98% from the prior close of $177.7. The stock opened at $178.66 and touched a ...

Researchers have applied AI to every step of the drug development process. But this might not be enough to design safe and ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbbVie (ABBV – Research Report), Palvella ...

GAMMA Investing LLC grew its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 9.5% during the fourth quarter, ...

Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...